Oligonucleotide Manufacturing Patents: Who Leads, Gaps Ahead 2026
Oligonucleotide manufacturing process patents: where synthesis claims concentrate and where they don't
27.3% of all 8,130 records sit with just five assignees, yet the ranked list runs 100 companies deep with a long tail of single- and few-filing entrants below tenth place. Filings rose to a peak of 247 in 2018, then eased; the 2021-to-2024 span shows a 32% decline (210 to 143), the last three-year comparison the dataset supports before the publication lag makes 2025 and 2026 numbers provisional. Treat the 2026 figure of 22 as a floor, not a signal that filing has stopped.
- 1SIRNA THERAPEUTICS INC10.9%
- 2CORIXA CORP5.9%
- 3IONIS PHARMACEUTICALS INC5.0%
- 4NANOSPHERE INC2.9%
- 5WAVE LIFE SCI LTD2.6%
See the full oligonucleotide manufacturing process analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in oligonucleotide manufacturing process technology?
One assignee leads the ranked list with 886 records, well ahead of fifth place at 209 and tenth place at 124. The top five assignees combined hold 27.3% of all 8,130 records in scope, and the top ten hold 36.2%. That still leaves the majority of the field spread across a ranking that runs 100 companies deep, so leadership at the top does not translate into control of the whole space.
Is oligonucleotide synthesis patent filing increasing or decreasing?
Filing peaked in 2018 at 247 records and has since eased; from 2021 (210) to 2024 (143) filings fell 32%, and 2024 is the most recent year the dataset treats as complete. Figures for 2025 and 2026 are still filling in because publication typically lags filing by around 18 months, so they should not yet be read as a continuing decline. The honest read is a cooling trend through the mid-2020s rather than a collapse.
What is the difference between chemical and enzymatic oligonucleotide synthesis in the patent data?
Chemical synthesis approaches, captured mainly under C12N and C07H, appear in roughly half of all 8,130 records (49.2% and 45.2% respectively), reflecting decades of phosphoramidite and solid-support chemistry claims. Enzymatic and fermentation-based routes, classified under C12P, appear in only 10.1% of records. That gap indicates enzymatic synthesis is a comparatively under-claimed manufacturing route rather than a mature, heavily contested one.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Oligonucleotide Manufacturing Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.